Detail akcie Aziyo Biologcs Rg-A online

Business Summary: Elutia Inc. is a commercial-stage company, which has developed a portfolio of products using both human and porcine tissue. Its portfolio of products spans the Women’s Health and Cardiovascular markets. In Women’s Health, it offers SimpliDerm, a novel biological matrix that leverages the inherent science of natural healing processes. SimpliDerm's design uses human-based hydrated acellular dermal matrix (ADM), which mitigates inflammation and enhances tissue incorporation. In Cardiovascular, it sells its specialized porcine small intestine submucosa for use as an intracardiac and vascular patch, as well as for pericardial reconstruction. In addition, its TYKE product is designed for use in the neonatal patient population. It is focused on advancing NXT-41x, a biomatrix that directly addresses the root causes of reconstruction infections following mastectomy. NXT-41x combines biologics and extended antibiotic release to provide protection while supporting tissue regeneration.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Elutia Inc revenues decreased 6% to $15.6M. Net loss before extraordinary items decreased 68% to $13.9M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects (Gain) loss on revaluation of warrant li increase from $15.3M (expense) to $12.5M (income).